Skeletal Dysplasia Market Size, Share & Trends Analysis Report By Treatment, By Type (Achondroplasia, X-linked Hypophosphatemia, Hypophosphatasia), By Region, And Segment Forecasts, 2019 - 2026

Published: Oct, 2019 | Pages: 90 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global skeletal dysplasia market size is expected to reach USD 3.6 billion by 2026, according to a new report by Grand View Research, Inc., registering a 4.0% CAGR over the forecast period. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.

Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.

Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.

The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals' Crysvita and Alexion Pharmaceuticals' Strensiq, respectively. Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.

Further key findings from the report suggest:

• Depending on the disorder, patients develop multiple symptoms ranging from spinal deformities to abnormal dental development. These disorders limit mobility and functional abilities in patients

• Commonly occurring deformities in these disorders include abnormal skeletal development that require orthopedic procedures and other interventions to relieve movement obstructions

• Early identification is crucial for timely medical management. The treatment for skeletal dysplasia is restricted largely to supportive care

• Surgical therapy is the most effective treatment option for achondroplasia type segment of skeletal dysplasia market. There is currently no definitive treatment for FOP. However, a brief course of high-dose corticosteroids, such as Prednisone, may help reduce intense inflammation and tissue swelling seen in early stages.

 Table of Contents

Chapter 1. Methodology and Scope
                     1.1. Market Segmentation & Scope
                     1.2. Market Definition
                     1.3. Information Procurement
                          1.3.1. Purchased Database
                          1.3.2. GVR's Internal Database
                          1.3.3. Secondary Sources & Third-Party Perspectives
                          1.3.4. Primary research
                     1.4. Information Analysis
                          1.4.1. Data Analysis Models
                     1.5. Market Formulation & Data Visualization
                     1.6. Data Validation & Publishing

Chapter 2. Executive Summary
                     2.1. Market Outlook
                     2.2. Segment Outlook
                     2.3. Competitive Insights

Chapter 3. Global Skeletal Dysplasia Market Variables, Trends & Scope
                     3.1. Skeletal Dysplasia Market Lineage outlook
                          3.1.1. Parent Market Outlook
                          3.1.2. Related/Ancillary Market Outlook
                     3.2. Penetration & Growth Prospect Mapping
                     3.3. Market Dynamics
                          3.3.1. Market Driver Analysis
                               3.3.1.1. Increasing prevalence of skeletal dysplasia
                               3.3.1.2. Presence of pipeline products
                          3.3.2. Market Restraint Analysis
                     3.4. Skeletal Dysplasia Market Analysis Tools
                          3.4.1. Industry Analysis - Porter's
                               3.4.1.1. Supplier Power: Moderate due to presence of many suppliers
                               3.4.1.2. Buyer Power: Moderate owing to presence of providers
                               3.4.1.3. Substitution Threat: Low owing to less/ no substitutes
                               3.4.1.4. Threat from New Entrant: Moderate due to emerging generics market
                               3.4.1.5. Competitive Rivalry: Moderate due to companies involved in research and development of novel products
                     3.5. PESTEL Analysis
                          3.5.1. Political Landscape
                          3.5.2. Environmental Landscape
                          3.5.3. Social Landscape
                          3.5.4. Technology Landscape
                          3.5.5. Legal Landscape

Chapter 4. Skeletal Dysplasia Market: Type Estimates & Trend Analysis
                     4.1. Definitions & Scope
                     4.2. Type Market Share Analysis, 2018 & 2026
                     4.3. Type Dashboard
                     4.4. Global Skeletal Dysplasia Market, By Type, 2015 to 2026
                     4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following:
                          4.5.1. X-linked hypophosphatemia
                               4.5.1.1. X-linked hypophosphatemia market, 2015 - 2026 (USD Million)
                          4.5.2. Hypophosphatasia
                               4.5.2.1. Hypophosphatasia market, 2015 - 2026 (USD Million)
                          4.5.3. Achondroplasia
                               4.5.3.1. Achondroplasia market, 2015 - 2026 (USD Million)
                          4.5.4. Fibrodysplasia ossificans progressive
                               4.5.4.1. Fibrodysplasia ossificans progressive market, 2015 - 2026 (USD Million)
                          4.5.5. Multiple osteochondromas
                               4.5.5.1. Multiple osteochondromas market, 2015 - 2026 (USD Million)
                          4.5.6. Others
                               4.5.6.1. Others market, 2015 - 2026 (USD Million)

Chapter 5. Skeletal Dysplasia Market: Treatment Estimates & Trend Analysis
                     5.1. Definitions & Scope
                     5.2. Treatment Market Share Analysis, 2018 & 2026
                     5.3. Treatment Dashboard
                     5.4. Global Skeletal Dysplasia Market, By Treatment, 2015 to 2026
                     5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following:
                          5.5.1. Medications
                               5.5.1.1. Medications market, 2015 - 2026 (USD Million)
                          5.5.2. Surgery
                               5.5.2.1. Surgery market, 2015 - 2026 (USD Million)
                          5.5.3. Others
                               5.5.3.1. Others market, 2015 - 2026 (USD Million)

Chapter 6. Skeletal Dysplasia Market: Regional Estimates & Trend analysis, by type, and treatment
                     6.1. Regional Market Snapshot
                     6.2. Regional Market Share and Leading Players, 2018
                          6.2.1. North America
                          6.2.2. Europe
                          6.2.3. Asia Pacific
                          6.2.4. Latin America
                          6.2.5. Middle East & Africa
                     6.3. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                          6.3.1. North America
                          6.3.2. Europe
                          6.3.3. Asia Pacific
                          6.3.4. Latin America
                          6.3.5. Middle East & Africa
                     6.4. Market Size, & Forecasts, and Trend Analysis, 2018 to 2026:
                          6.4.1. North America
                               6.4.1.1. North America skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.1.2. U.S.
                                    6.4.1.2.1. U.S. skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.1.3. Canada
                                    6.4.1.3.1. Canada skeletal dysplasia market, 2015 - 2026 (USD Million)
                          6.4.2. Europe
                               6.4.2.1. Europe skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.2.2. U.K.
                                    6.4.2.2.1. U.K. skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.2.3. Germany
                                    6.4.2.3.1. Germany skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.2.4. Spain
                                    6.4.2.4.1. Spain skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.2.5. France
                                    6.4.2.5.1. France skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.2.6. Italy
                                    6.4.2.6.1. Italy skeletal dysplasia market, 2015 - 2026 (USD Million)
                          6.4.3. Asia Pacific
                               6.4.3.1. Asia Pacific skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.3.2. China
                                    6.4.3.2.1. China skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.3.3. Japan
                                    6.4.3.3.1. Japan skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.3.4. India
                                    6.4.3.4.1. India skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.3.5. South Korea
                                    6.4.3.5.1. South Korea skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.3.6. Australia
                                    6.4.3.6.1. Australia skeletal dysplasia market, 2015 - 2026 (USD Million)
                          6.4.4. Latin America
                               6.4.4.1. Latin America skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.4.2. Brazil
                                    6.4.4.2.1. Brazil skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.4.3. Mexico
                                    6.4.4.3.1. Mexico skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.4.4. Argentina
                                    6.4.4.4.1. Argentina skeletal dysplasia market, 2015 - 2026 (USD Million)
                          6.4.5. Middle East Africa
                               6.4.5.1. MEA skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.5.2. South Africa
                                    6.4.5.2.1. South Africa skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.5.3. Saudi Arabia
                                    6.4.5.3.1. Saudi Arabia skeletal dysplasia market, 2015 - 2026 (USD Million)
                               6.4.5.4. UAE
                                    6.4.5.4.1. UAE skeletal dysplasia market, 2015 - 2026 (USD Million)

Chapter 7. Company Profiles
                     7.1. Recent developments & impact analysis, by key market participants
                     7.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
                     7.3. Public Companies
                          7.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                          7.3.2. Competitive Dashboard Analysis
                          7.3.3. Market Differentiators
                     7.4. Private Companies
                          7.4.1. Regional network map
                     7.5. Strategic Framework
                          7.5.1. BioMarin
                               7.5.1.1. Company Overview
                               7.5.1.2. Financial Performance
                               7.5.1.3. Product Benchmarking
                               7.5.1.4. Strategic Initiatives
                          7.5.2. Amgen, Inc.
                               7.5.2.1. Company Overview
                               7.5.2.2. Financial Performance
                               7.5.2.3. Product Benchmarking
                               7.5.2.4. Strategic Initiatives
                          7.5.3. Merck KGaA
                               7.5.3.1. Company Overview
                               7.5.3.2. Financial Performance
                               7.5.3.3. Product Benchmarking
                               7.5.3.4. Strategic Initiatives
                          7.5.4. Regeneron
                               7.5.4.1. Company Overview
                               7.5.4.2. Financial Performance
                               7.5.4.3. Product Benchmarking
                               7.5.4.4. Strategic Initiatives
                          7.5.5. Alexion Pharmaceuticals, Inc.
                               7.5.5.1. Company Overview
                               7.5.5.2. Financial Performance
                               7.5.5.3. Product Benchmarking
                               7.5.5.4. Strategic Initiatives
                          7.5.6. Clementia (Ipsen Group)
                               7.5.6.1. Company Overview
                               7.5.6.2. Financial Performance
                               7.5.6.3. Product Benchmarking
                               7.5.6.4. Strategic Initiatives

List of Tables

TABLE 1 List of Abbreviation
TABLE 2 North America Skeletal Dysplasia Market, By Country, 2015 - 2026 (USD Million)
TABLE 3 North America Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 4 North America Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 5 U.S. Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 6 U.S. Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 7 Canada Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 8 Canada Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 9 Europe Skeletal Dysplasia Market, By Country, 2015 - 2026 (USD Million)
TABLE 10 Europe Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 11 Europe Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 12 U.K. Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 13 U.K. Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 14 Germany Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 15 Germany Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 16 France Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 17 France Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 18 Italy Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 19 Italy Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 20 Spain Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 21 Spain Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 22 Asia Pacific Skeletal Dysplasia Market, By Country, 2015 - 2026 (USD Million)
TABLE 23 Asia Pacific Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 24 Asia Pacific Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 25 Japan Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 26 Japan Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 27 China Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 28 China Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 29 India Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 30 India Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 31 South Korea Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 32 South Korea Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 33 Australia Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 34 Australia Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 35 Latin America Skeletal Dysplasia Market, By Country, 2015 - 2026 (USD Million)
TABLE 36 Latin America Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 37 Latin America Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 38 Mexico Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 39 Mexico Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 40 Brazil Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 41 Brazil Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 42 Argentina Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 43 Argentina Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 44 MEA Skeletal Dysplasia Market, By Country, 2015 - 2026 (USD Million)
TABLE 45 MEA Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 46 MEA Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 47 South Africa Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 48 South Africa Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 49 Saudi Arabia Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 50 Saudi Arabia Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)
TABLE 51 UAE Skeletal Dysplasia Market, By Type, 2015 - 2026 (USD Million)
TABLE 52 UAE Skeletal Dysplasia Market, By Treatment, 2015 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary
FIG. 4 Market segmentation & scope
FIG. 5 Market size and growth prospects
FIG. 6 Global skeletal dysplasia market- Key market driver analysis
FIG. 7 Global skeletal dysplasia market - Key market restraint analysis
FIG. 8 Penetration & growth prospect mapping
FIG. 9 Factors estimated to impact on market growth
FIG. 10 Global skeletal dysplasia market - Porter's analysis
FIG. 11 Global skeletal dysplasia market - PESTEL analysis
FIG. 12 Global skeletal dysplasia market type outlook key takeaways
FIG. 13 Global skeletal dysplasia market: Type movement analysis
FIG. 14 X-linked hypophosphatemia market estimates & forecast & forecast, 2015 - 2026 (USD Million)
FIG. 15 Hypophosphatasia market estimates, 2015 - 2026 (USD Million)
FIG. 16 Achondroplasia market estimates, 2015 - 2026 (USD Million)
FIG. 17 Fibrodysplasia ossificans progressive market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 18 Multiple osteochondromas market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 19 Others market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 20 Global skeletal dysplasia market treatment outlook key takeaways
FIG. 21 Global skeletal dysplasia market: Treatment movement analysis
FIG. 22 Medication market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 23 Surgery market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 24 Others market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 25 Regional market place: Key takeaways
FIG. 26 Global skeletal dysplasia market: Regional movement analysis
FIG. 27 North America skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 28 U.S. skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 29 Canada skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 30 Europe skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 31 U.K. skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 32 Germany skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 33 France skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 34 Spain skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 35 Italy skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 36 Asia Pacific skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 37 Japan skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 38 China skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 39 India skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 40 South Korea skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 41 Australia skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 42 Latin America skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 43 Brazil skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 44 Mexico skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 45 Argentina skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 46 MEA skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 47 South Africa skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 48 Saudi Arabia skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 49 UAE skeletal dysplasia market estimates & forecast, 2015 - 2026 (USD Million)
FIG. 50 Strategy framework